ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2012
Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00621192 (Multiple Dose Pharmacokinetic Study of Meropenem in Young Infants), which is not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multiple Dose Pharmacokinetic Study of Meropenem in Young Infants (<91 Days) With Suspected or Complicated Intra-abdominal Infections
Who cites it
32 citing papers in PubMed, 66 citations in OpenAlex.
- Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial.PloS one · 2020Trial
- Efficacy and Safety of Meropenem in Pregnant Women with Upper Urinary Tract Infections: A Retrospective Cohort Study in Romania.Antibiotics (Basel, Switzerland) · 2026Article
- Salvage Treatment of Ventilator-Associated Pneumonia Using Sulbactam-Durlobactam in a Preterm Neonate: A Case Report.Infectious disease reports · 2026Article
- Effectiveness, Tolerance, and Safety of Meropenem in a Pediatric Outpatient Parenteral Antimicrobial Therapy Program.The Canadian journal of hospital pharmacy · 2025Article
- Creativity in Pediatric Clinical Pharmacology: Study Design and Oral Dosage Forms.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2024Article
- Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model-based approach.Pharmacology research & perspectives · 2024Article
- Meropenem Disposition in Neonatal and Pediatric Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy.Antibiotics (Basel, Switzerland) · 2024Article
- The association of hypokalemia with meropenem administration: A case report and literature review.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2024Article
- Population PK/PD modelling of meropenem in preterm newborns based on therapeutic drug monitoring data.Frontiers in pharmacology · 2023Article
- Editorial: Therapeutic drug monitoring (TDM): a useful tool for pediatric pharmacology applied to routine clinical practice, Volume II.Frontiers in pharmacology · 2023Article
- Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis.Children (Basel, Switzerland) · 2022Article
- Use of Antibiotics in Preterm Newborns.Antibiotics (Basel, Switzerland) · 2022Review
- Improving the efficacy for meropenem therapy requires a high probability of target attainment in critically ill infants and children.Frontiers in pharmacology · 2022Article
- Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants.Clinical pharmacokinetics · 2021Article
- Association between neonatal intensive care unit medication safety practices, adverse events, and death.Journal of perinatology : official journal of the California Perinatal Association · 2021Article
- Use of Meropenem in a Tertiary Pediatric Hospital in Costa Rica and Its Role in the Era of Antimicrobial Stewardship.Cureus · 2021Article
- Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs.Pharmaceutics · 2020Article
- Cross-sectional study of drug utilisation in a Chinese neonatal unit.The Journal of international medical research · 2020Article
- Dosage Regimens for Meropenem in Children with Pseudomonas Infections Do Not Meet Serum Concentration Targets.Clinical and translational science · 2020Article
- Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.Antimicrobial agents and chemotherapy · 2020Review
Corrections and comments
- Commented on by
Authors and funding
30 authors at 20 institutions in 1 country.
Funding
Abstract
backgroundIntra-abdominal infections are common in young infants and lead to significant morbidity and mortality. Meropenem is a broad-spectrum antimicrobial with excellent activity against pathogens associated with intra-abdominal infections. The purpose of this study was to determine the safety and effectiveness of meropenem in young infants with suspected or complicated intra-abdominal infections.
methodsPreterm and term infants <91 days of age with suspected or confirmed intra-abdominal infections hospitalized in 24 neonatal intensive care units were studied in an open-label, multiple-dose study. Adverse events and serious adverse events were collected through 3 and 30 days following the last meropenem dose, respectively. Effectiveness was assessed by 3 criteria: death, bacterial cultures, and presumptive clinical cure score.
resultsOf 200 subjects enrolled in the study, 99 (50%) experienced an adverse event, and 34 (17%) had serious adverse events; no adverse events were probably or definitely related to meropenem. The most commonly reported adverse events were sepsis (6%), seizures (5%), elevated conjugated bilirubin (5%), and hypokalemia (5%). Only 2 of the serious adverse events were determined to be possibly related to meropenem (isolated ileal perforation and an episode of fungal sepsis). Effectiveness was evaluable in 192 (96%) subjects, and overall treatment success was 84%.
conclusionsMeropenem was well tolerated in this cohort of critically ill infants, and the majority of infants treated with meropenem met the definition of therapeutic success. CLINICAL TRIALS REGISTRATION: NCT00621192.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.